Pawel Krysiak | Gene Therapy and Precision Medicine for Neurodegenerative Disease
Pawel Krysiak joins Executive Insights for Life Sciences Innovators to discuss CNS-directed gene therapy, precision medicine, neurodegenerative disease, and the leadership challenges of building an early-stage biotechnology company.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Pawel Krysiak discusses how Jaya Biosciences is developing CNS-directed gene therapies for genetically defined neurodegenerative diseases. The conversation explores the role of lysosomal enzyme gene heterozygosity in adult-onset neurodegeneration, precision medicine approaches for Alzheimer’s disease and related disorders, and the leadership required to translate early-stage science into development-ready therapeutic programs.
Key Themes
- CNS-directed gene therapy
- Precision medicine for neurodegenerative diseases
- Alzheimer’s disease and genetically defined neurological disorders
- Lysosomal enzyme biology and therapeutic innovation
- Translating early-stage science into clinical development
- Building development-stage biotechnology companies
Why This Matters for Life Sciences Leaders
Neurodegenerative diseases remain among the most challenging areas in medicine, requiring innovative approaches that combine advances in genetics, neuroscience, and precision medicine. The conversation highlights how emerging gene therapy platforms are expanding opportunities to address previously untreatable conditions while illustrating the leadership, scientific discipline, and strategic execution required to advance novel therapies toward the clinic.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
